Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 USD | -0.54% | +3.11% | -2.41% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.41% | 417M | C | ||
+16.73% | 123B | B+ | ||
+13.04% | 107B | B+ | ||
-5.80% | 24.01B | B+ | ||
+1.69% | 22.59B | B | ||
-10.09% | 18.16B | A- | ||
-40.52% | 16.84B | A- | ||
-14.00% | 16.23B | B | ||
+1.18% | 13.43B | C+ | ||
+24.18% | 11.32B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FATE Stock
- Ratings Fate Therapeutics, Inc.